Global Self Amplifying RNA Vaccine Market Growth 2025-2031

July 2025 | 111 pages | ID: S1491688C241EN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Self Amplifying RNA Vaccine market size is predicted to grow from US$ 414 million in 2025 to US$ 581 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.

Self-amplifying RNA vaccine, or SAM vaccine, is an innovative vaccine type based on mRNA technology. Compared with conventional mRNA vaccines, self-amplifying RNA vaccines can replicate and express antigen proteins within cells, significantly increasing antigen production and duration, and enhancing immune responses. This vaccine uses vectors such as alphaviruses to introduce mRNA encoding antigen proteins into human cells, where they replicate and express to form large amounts of antigen proteins, subsequently inducing a strong immune response in the human body. Self-amplifying RNA vaccines offer advantages such as simple production processes, easy scalability, and rapid response to viral mutations, providing a powerful tool for addressing emerging and sudden infectious diseases.

United States market for Self Amplifying RNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Self Amplifying RNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Self Amplifying RNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Self Amplifying RNA Vaccine players cover Arcturus Therapeutics, CSL, Gennova Biopharmaceuticals, Genvax Technologies, Merck Animal Health, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Self Amplifying RNA Vaccine Industry Forecast” looks at past sales and reviews total world Self Amplifying RNA Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Self Amplifying RNA Vaccine sales for 2025 through 2031. With Self Amplifying RNA Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Self Amplifying RNA Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Self Amplifying RNA Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Self Amplifying RNA Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Self Amplifying RNA Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Self Amplifying RNA Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Self Amplifying RNA Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Self Amplifying RNA Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
  • Veterinary Use Self Amplifying RNA Vaccine
  • Human Use Self Amplifying RNA Vaccine
Segmentation by Application:
  • Hospital
  • Clinic
  • CDC
  • Others
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
  • Arcturus Therapeutics
  • CSL
  • Gennova Biopharmaceuticals
  • Genvax Technologies
  • Merck Animal Health
  • VLP Therapeutics
  • Chimeron Bio
  • Eyam Vaccines and Immunotherapeutics
  • Ziphius
  • Pfizer
  • BioNTech
Key Questions Addressed in this Report

What is the 10-year outlook for the global Self Amplifying RNA Vaccine market?
What factors are driving Self Amplifying RNA Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Self Amplifying RNA Vaccine market opportunities vary by end market size?
How does Self Amplifying RNA Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Self Amplifying RNA Vaccine Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Self Amplifying RNA Vaccine by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Self Amplifying RNA Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Self Amplifying RNA Vaccine Segment by Type
  2.2.1 Veterinary Use Self Amplifying RNA Vaccine
  2.2.2 Human Use Self Amplifying RNA Vaccine
2.3 Self Amplifying RNA Vaccine Sales by Type
  2.3.1 Global Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)
  2.3.2 Global Self Amplifying RNA Vaccine Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Self Amplifying RNA Vaccine Sale Price by Type (2020-2025)
2.4 Self Amplifying RNA Vaccine Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
  2.4.3 CDC
  2.4.4 Others
2.5 Self Amplifying RNA Vaccine Sales by Application
  2.5.1 Global Self Amplifying RNA Vaccine Sale Market Share by Application (2020-2025)
  2.5.2 Global Self Amplifying RNA Vaccine Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Self Amplifying RNA Vaccine Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Self Amplifying RNA Vaccine Breakdown Data by Company
  3.1.1 Global Self Amplifying RNA Vaccine Annual Sales by Company (2020-2025)
  3.1.2 Global Self Amplifying RNA Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Self Amplifying RNA Vaccine Annual Revenue by Company (2020-2025)
  3.2.1 Global Self Amplifying RNA Vaccine Revenue by Company (2020-2025)
  3.2.2 Global Self Amplifying RNA Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Self Amplifying RNA Vaccine Sale Price by Company
3.4 Key Manufacturers Self Amplifying RNA Vaccine Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Self Amplifying RNA Vaccine Product Location Distribution
  3.4.2 Players Self Amplifying RNA Vaccine Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SELF AMPLIFYING RNA VACCINE BY GEOGRAPHIC REGION

4.1 World Historic Self Amplifying RNA Vaccine Market Size by Geographic Region (2020-2025)
  4.1.1 Global Self Amplifying RNA Vaccine Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Self Amplifying RNA Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Self Amplifying RNA Vaccine Market Size by Country/Region (2020-2025)
  4.2.1 Global Self Amplifying RNA Vaccine Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Self Amplifying RNA Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Self Amplifying RNA Vaccine Sales Growth
4.4 APAC Self Amplifying RNA Vaccine Sales Growth
4.5 Europe Self Amplifying RNA Vaccine Sales Growth
4.6 Middle East & Africa Self Amplifying RNA Vaccine Sales Growth

5 AMERICAS

5.1 Americas Self Amplifying RNA Vaccine Sales by Country
  5.1.1 Americas Self Amplifying RNA Vaccine Sales by Country (2020-2025)
  5.1.2 Americas Self Amplifying RNA Vaccine Revenue by Country (2020-2025)
5.2 Americas Self Amplifying RNA Vaccine Sales by Type (2020-2025)
5.3 Americas Self Amplifying RNA Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Self Amplifying RNA Vaccine Sales by Region
  6.1.1 APAC Self Amplifying RNA Vaccine Sales by Region (2020-2025)
  6.1.2 APAC Self Amplifying RNA Vaccine Revenue by Region (2020-2025)
6.2 APAC Self Amplifying RNA Vaccine Sales by Type (2020-2025)
6.3 APAC Self Amplifying RNA Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Self Amplifying RNA Vaccine by Country
  7.1.1 Europe Self Amplifying RNA Vaccine Sales by Country (2020-2025)
  7.1.2 Europe Self Amplifying RNA Vaccine Revenue by Country (2020-2025)
7.2 Europe Self Amplifying RNA Vaccine Sales by Type (2020-2025)
7.3 Europe Self Amplifying RNA Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Self Amplifying RNA Vaccine by Country
  8.1.1 Middle East & Africa Self Amplifying RNA Vaccine Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Self Amplifying RNA Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Self Amplifying RNA Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Self Amplifying RNA Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Self Amplifying RNA Vaccine
10.3 Manufacturing Process Analysis of Self Amplifying RNA Vaccine
10.4 Industry Chain Structure of Self Amplifying RNA Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Self Amplifying RNA Vaccine Distributors
11.3 Self Amplifying RNA Vaccine Customer

12 WORLD FORECAST REVIEW FOR SELF AMPLIFYING RNA VACCINE BY GEOGRAPHIC REGION

12.1 Global Self Amplifying RNA Vaccine Market Size Forecast by Region
  12.1.1 Global Self Amplifying RNA Vaccine Forecast by Region (2026-2031)
  12.1.2 Global Self Amplifying RNA Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Self Amplifying RNA Vaccine Forecast by Type (2026-2031)
12.7 Global Self Amplifying RNA Vaccine Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Arcturus Therapeutics
  13.1.1 Arcturus Therapeutics Company Information
  13.1.2 Arcturus Therapeutics Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.1.3 Arcturus Therapeutics Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Arcturus Therapeutics Main Business Overview
  13.1.5 Arcturus Therapeutics Latest Developments
13.2 CSL
  13.2.1 CSL Company Information
  13.2.2 CSL Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.2.3 CSL Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 CSL Main Business Overview
  13.2.5 CSL Latest Developments
13.3 Gennova Biopharmaceuticals
  13.3.1 Gennova Biopharmaceuticals Company Information
  13.3.2 Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.3.3 Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Gennova Biopharmaceuticals Main Business Overview
  13.3.5 Gennova Biopharmaceuticals Latest Developments
13.4 Genvax Technologies
  13.4.1 Genvax Technologies Company Information
  13.4.2 Genvax Technologies Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.4.3 Genvax Technologies Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Genvax Technologies Main Business Overview
  13.4.5 Genvax Technologies Latest Developments
13.5 Merck Animal Health
  13.5.1 Merck Animal Health Company Information
  13.5.2 Merck Animal Health Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.5.3 Merck Animal Health Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Merck Animal Health Main Business Overview
  13.5.5 Merck Animal Health Latest Developments
13.6 VLP Therapeutics
  13.6.1 VLP Therapeutics Company Information
  13.6.2 VLP Therapeutics Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.6.3 VLP Therapeutics Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 VLP Therapeutics Main Business Overview
  13.6.5 VLP Therapeutics Latest Developments
13.7 Chimeron Bio
  13.7.1 Chimeron Bio Company Information
  13.7.2 Chimeron Bio Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.7.3 Chimeron Bio Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Chimeron Bio Main Business Overview
  13.7.5 Chimeron Bio Latest Developments
13.8 Eyam Vaccines and Immunotherapeutics
  13.8.1 Eyam Vaccines and Immunotherapeutics Company Information
  13.8.2 Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.8.3 Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Eyam Vaccines and Immunotherapeutics Main Business Overview
  13.8.5 Eyam Vaccines and Immunotherapeutics Latest Developments
13.9 Ziphius
  13.9.1 Ziphius Company Information
  13.9.2 Ziphius Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.9.3 Ziphius Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Ziphius Main Business Overview
  13.9.5 Ziphius Latest Developments
13.10 Pfizer
  13.10.1 Pfizer Company Information
  13.10.2 Pfizer Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.10.3 Pfizer Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 Pfizer Main Business Overview
  13.10.5 Pfizer Latest Developments
13.11 BioNTech
  13.11.1 BioNTech Company Information
  13.11.2 BioNTech Self Amplifying RNA Vaccine Product Portfolios and Specifications
  13.11.3 BioNTech Self Amplifying RNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.11.4 BioNTech Main Business Overview
  13.11.5 BioNTech Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Self Amplifying RNA Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Self Amplifying RNA Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Veterinary Use Self Amplifying RNA Vaccine
Table 4. Major Players of Human Use Self Amplifying RNA Vaccine
Table 5. Global Self Amplifying RNA Vaccine Sales by Type (2020-2025) & (Units)
Table 6. Global Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)
Table 7. Global Self Amplifying RNA Vaccine Revenue by Type (2020-2025) & ($ million)
Table 8. Global Self Amplifying RNA Vaccine Revenue Market Share by Type (2020-2025)
Table 9. Global Self Amplifying RNA Vaccine Sale Price by Type (2020-2025) & (US$/Unit)
Table 10. Global Self Amplifying RNA Vaccine Sale by Application (2020-2025) & (Units)
Table 11. Global Self Amplifying RNA Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global Self Amplifying RNA Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global Self Amplifying RNA Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global Self Amplifying RNA Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 15. Global Self Amplifying RNA Vaccine Sales by Company (2020-2025) & (Units)
Table 16. Global Self Amplifying RNA Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global Self Amplifying RNA Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Self Amplifying RNA Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global Self Amplifying RNA Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 20. Key Manufacturers Self Amplifying RNA Vaccine Producing Area Distribution and Sales Area
Table 21. Players Self Amplifying RNA Vaccine Products Offered
Table 22. Self Amplifying RNA Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Self Amplifying RNA Vaccine Sales by Geographic Region (2020-2025) & (Units)
Table 26. Global Self Amplifying RNA Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global Self Amplifying RNA Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Self Amplifying RNA Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Self Amplifying RNA Vaccine Sales by Country/Region (2020-2025) & (Units)
Table 30. Global Self Amplifying RNA Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global Self Amplifying RNA Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Self Amplifying RNA Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)
Table 34. Americas Self Amplifying RNA Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas Self Amplifying RNA Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Self Amplifying RNA Vaccine Sales by Type (2020-2025) & (Units)
Table 37. Americas Self Amplifying RNA Vaccine Sales by Application (2020-2025) & (Units)
Table 38. APAC Self Amplifying RNA Vaccine Sales by Region (2020-2025) & (Units)
Table 39. APAC Self Amplifying RNA Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC Self Amplifying RNA Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Self Amplifying RNA Vaccine Sales by Type (2020-2025) & (Units)
Table 42. APAC Self Amplifying RNA Vaccine Sales by Application (2020-2025) & (Units)
Table 43. Europe Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)
Table 44. Europe Self Amplifying RNA Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Self Amplifying RNA Vaccine Sales by Type (2020-2025) & (Units)
Table 46. Europe Self Amplifying RNA Vaccine Sales by Application (2020-2025) & (Units)
Table 47. Middle East & Africa Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)
Table 48. Middle East & Africa Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Self Amplifying RNA Vaccine Sales by Type (2020-2025) & (Units)
Table 50. Middle East & Africa Self Amplifying RNA Vaccine Sales by Application (2020-2025) & (Units)
Table 51. Key Market Drivers & Growth Opportunities of Self Amplifying RNA Vaccine
Table 52. Key Market Challenges & Risks of Self Amplifying RNA Vaccine
Table 53. Key Industry Trends of Self Amplifying RNA Vaccine
Table 54. Self Amplifying RNA Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Self Amplifying RNA Vaccine Distributors List
Table 57. Self Amplifying RNA Vaccine Customer List
Table 58. Global Self Amplifying RNA Vaccine Sales Forecast by Region (2026-2031) & (Units)
Table 59. Global Self Amplifying RNA Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Self Amplifying RNA Vaccine Sales Forecast by Country (2026-2031) & (Units)
Table 61. Americas Self Amplifying RNA Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Self Amplifying RNA Vaccine Sales Forecast by Region (2026-2031) & (Units)
Table 63. APAC Self Amplifying RNA Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Self Amplifying RNA Vaccine Sales Forecast by Country (2026-2031) & (Units)
Table 65. Europe Self Amplifying RNA Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Self Amplifying RNA Vaccine Sales Forecast by Country (2026-2031) & (Units)
Table 67. Middle East & Africa Self Amplifying RNA Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Self Amplifying RNA Vaccine Sales Forecast by Type (2026-2031) & (Units)
Table 69. Global Self Amplifying RNA Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Self Amplifying RNA Vaccine Sales Forecast by Application (2026-2031) & (Units)
Table 71. Global Self Amplifying RNA Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Arcturus Therapeutics Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Arcturus Therapeutics Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 74. Arcturus Therapeutics Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Arcturus Therapeutics Main Business
Table 76. Arcturus Therapeutics Latest Developments
Table 77. CSL Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. CSL Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 79. CSL Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. CSL Main Business
Table 81. CSL Latest Developments
Table 82. Gennova Biopharmaceuticals Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 84. Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Gennova Biopharmaceuticals Main Business
Table 86. Gennova Biopharmaceuticals Latest Developments
Table 87. Genvax Technologies Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Genvax Technologies Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 89. Genvax Technologies Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Genvax Technologies Main Business
Table 91. Genvax Technologies Latest Developments
Table 92. Merck Animal Health Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck Animal Health Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 94. Merck Animal Health Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Merck Animal Health Main Business
Table 96. Merck Animal Health Latest Developments
Table 97. VLP Therapeutics Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. VLP Therapeutics Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 99. VLP Therapeutics Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. VLP Therapeutics Main Business
Table 101. VLP Therapeutics Latest Developments
Table 102. Chimeron Bio Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Chimeron Bio Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 104. Chimeron Bio Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Chimeron Bio Main Business
Table 106. Chimeron Bio Latest Developments
Table 107. Eyam Vaccines and Immunotherapeutics Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 109. Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Eyam Vaccines and Immunotherapeutics Main Business
Table 111. Eyam Vaccines and Immunotherapeutics Latest Developments
Table 112. Ziphius Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Ziphius Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 114. Ziphius Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. Ziphius Main Business
Table 116. Ziphius Latest Developments
Table 117. Pfizer Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Pfizer Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 119. Pfizer Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. Pfizer Main Business
Table 121. Pfizer Latest Developments
Table 122. BioNTech Basic Information, Self Amplifying RNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. BioNTech Self Amplifying RNA Vaccine Product Portfolios and Specifications
Table 124. BioNTech Self Amplifying RNA Vaccine Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. BioNTech Main Business
Table 126. BioNTech Latest Developments

LIST OF FIGURES

Figure 1. Picture of Self Amplifying RNA Vaccine
Figure 2. Self Amplifying RNA Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Self Amplifying RNA Vaccine Sales Growth Rate 2020-2031 (Units)
Figure 7. Global Self Amplifying RNA Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Self Amplifying RNA Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Self Amplifying RNA Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Self Amplifying RNA Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Veterinary Use Self Amplifying RNA Vaccine
Figure 12. Product Picture of Human Use Self Amplifying RNA Vaccine
Figure 13. Global Self Amplifying RNA Vaccine Sales Market Share by Type in 2025
Figure 14. Global Self Amplifying RNA Vaccine Revenue Market Share by Type (2020-2025)
Figure 15. Self Amplifying RNA Vaccine Consumed in Hospital
Figure 16. Global Self Amplifying RNA Vaccine Market: Hospital (2020-2025) & (Units)
Figure 17. Self Amplifying RNA Vaccine Consumed in Clinic
Figure 18. Global Self Amplifying RNA Vaccine Market: Clinic (2020-2025) & (Units)
Figure 19. Self Amplifying RNA Vaccine Consumed in CDC
Figure 20. Global Self Amplifying RNA Vaccine Market: CDC (2020-2025) & (Units)
Figure 21. Self Amplifying RNA Vaccine Consumed in Others
Figure 22. Global Self Amplifying RNA Vaccine Market: Others (2020-2025) & (Units)
Figure 23. Global Self Amplifying RNA Vaccine Sale Market Share by Application (2024)
Figure 24. Global Self Amplifying RNA Vaccine Revenue Market Share by Application in 2025
Figure 25. Self Amplifying RNA Vaccine Sales by Company in 2025 (Units)
Figure 26. Global Self Amplifying RNA Vaccine Sales Market Share by Company in 2025
Figure 27. Self Amplifying RNA Vaccine Revenue by Company in 2025 ($ millions)
Figure 28. Global Self Amplifying RNA Vaccine Revenue Market Share by Company in 2025
Figure 29. Global Self Amplifying RNA Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Self Amplifying RNA Vaccine Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Self Amplifying RNA Vaccine Sales 2020-2025 (Units)
Figure 32. Americas Self Amplifying RNA Vaccine Revenue 2020-2025 ($ millions)
Figure 33. APAC Self Amplifying RNA Vaccine Sales 2020-2025 (Units)
Figure 34. APAC Self Amplifying RNA Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Europe Self Amplifying RNA Vaccine Sales 2020-2025 (Units)
Figure 36. Europe Self Amplifying RNA Vaccine Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Self Amplifying RNA Vaccine Sales 2020-2025 (Units)
Figure 38. Middle East & Africa Self Amplifying RNA Vaccine Revenue 2020-2025 ($ millions)
Figure 39. Americas Self Amplifying RNA Vaccine Sales Market Share by Country in 2025
Figure 40. Americas Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2025)
Figure 41. Americas Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)
Figure 42. Americas Self Amplifying RNA Vaccine Sales Market Share by Application (2020-2025)
Figure 43. United States Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Self Amplifying RNA Vaccine Sales Market Share by Region in 2025
Figure 48. APAC Self Amplifying RNA Vaccine Revenue Market Share by Region (2020-2025)
Figure 49. APAC Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)
Figure 50. APAC Self Amplifying RNA Vaccine Sales Market Share by Application (2020-2025)
Figure 51. China Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. India Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Self Amplifying RNA Vaccine Sales Market Share by Country in 2025
Figure 59. Europe Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2025)
Figure 60. Europe Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)
Figure 61. Europe Self Amplifying RNA Vaccine Sales Market Share by Application (2020-2025)
Figure 62. Germany Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. France Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Self Amplifying RNA Vaccine Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Self Amplifying RNA Vaccine Sales Market Share by Application (2020-2025)
Figure 70. Egypt Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Self Amplifying RNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Self Amplifying RNA Vaccine in 2025
Figure 76. Manufacturing Process Analysis of Self Amplifying RNA Vaccine
Figure 77. Industry Chain Structure of Self Amplifying RNA Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Self Amplifying RNA Vaccine Sales Market Forecast by Region (2026-2031)
Figure 80. Global Self Amplifying RNA Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Self Amplifying RNA Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Self Amplifying RNA Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Self Amplifying RNA Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Self Amplifying RNA Vaccine Revenue Market Share Forecast by Application (2026-2031)